IL226271A - The prolactin receptor antagonist and chemotherapy drug for ovarian cancer treatment - Google Patents

The prolactin receptor antagonist and chemotherapy drug for ovarian cancer treatment

Info

Publication number
IL226271A
IL226271A IL226271A IL22627113A IL226271A IL 226271 A IL226271 A IL 226271A IL 226271 A IL226271 A IL 226271A IL 22627113 A IL22627113 A IL 22627113A IL 226271 A IL226271 A IL 226271A
Authority
IL
Israel
Prior art keywords
ovarian cancer
receptor antagonist
chemotherapeutic drug
prolactin receptor
treating ovarian
Prior art date
Application number
IL226271A
Other languages
English (en)
Hebrew (he)
Other versions
IL226271A0 (en
Original Assignee
Oncolix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolix Inc filed Critical Oncolix Inc
Publication of IL226271A0 publication Critical patent/IL226271A0/en
Publication of IL226271A publication Critical patent/IL226271A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL226271A 2010-11-17 2013-05-09 The prolactin receptor antagonist and chemotherapy drug for ovarian cancer treatment IL226271A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/948,329 US8648046B2 (en) 2009-02-26 2010-11-17 Compositions and methods for visualizing and eliminating cancer stem cells
PCT/US2011/061040 WO2012068282A1 (en) 2010-11-17 2011-11-16 Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer

Publications (2)

Publication Number Publication Date
IL226271A0 IL226271A0 (en) 2013-07-31
IL226271A true IL226271A (en) 2017-05-29

Family

ID=45349276

Family Applications (1)

Application Number Title Priority Date Filing Date
IL226271A IL226271A (en) 2010-11-17 2013-05-09 The prolactin receptor antagonist and chemotherapy drug for ovarian cancer treatment

Country Status (9)

Country Link
US (2) US8648046B2 (https=)
EP (1) EP2640412B1 (https=)
JP (3) JP6306886B2 (https=)
KR (1) KR20140009196A (https=)
CN (2) CN103298481A (https=)
AU (1) AU2011328935B2 (https=)
CA (1) CA2817846A1 (https=)
IL (1) IL226271A (https=)
WO (1) WO2012068282A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167750A2 (en) * 2012-05-11 2013-11-14 Prorec Bio Ab Method for diagnosis and treatment of prolactin associated disorders
CN105102480B (zh) 2012-12-24 2019-04-16 艾伯维公司 催乳素受体结合蛋白及其用途
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
EP3707166A4 (en) * 2017-11-06 2021-11-24 Daniel J. Monticello CHEMICAL ANTIGENIC RECEPTOR SYSTEMS WITH NEGATIVE DOMINANT LIGAND
WO2019169330A1 (en) * 2018-03-02 2019-09-06 Oncolix, Inc. Method for treating cancers expressing prolactin receptor
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN113956356B (zh) * 2021-10-27 2023-05-02 福州迈新生物技术开发有限公司 抗prl蛋白单克隆抗体、细胞系及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1055932A (en) 1975-10-22 1979-06-05 Hematech Inc. Blood substitute based on hemoglobin
DE2616086C2 (de) 1976-04-13 1986-04-03 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Substanz zur Verwendung in einem kolloidalen Blutvolumenersatzmittel aus Hydroxyethylstärke und Hämoglobin
EP1079851B1 (en) * 1998-05-12 2007-07-04 Greenville Hospital System Use of anti-prolactin agents to treat cancer
EP2180054A1 (en) * 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1282642B1 (en) * 2000-05-09 2006-09-06 Greenville Hospital System Therapeutic pore-forming peptides
US7001888B2 (en) * 2002-03-29 2006-02-21 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
BR0314106A (pt) 2002-09-11 2005-07-19 Fresenius Kabi De Gmbh Polipeptìdeos hasilados, especialmente eritropoietina hasilada
NZ541122A (en) * 2002-12-26 2008-09-26 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
US8754031B2 (en) * 2004-03-08 2014-06-17 Oncolix, Inc. Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
US20050238628A1 (en) * 2004-04-08 2005-10-27 Blau Carl A Methods for treating cancer
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
CN100479863C (zh) * 2006-09-06 2009-04-22 中国医学科学院北京协和医院 Cofilin 1与癌症的紫杉烷类化疗药物耐药性的相关性
EP2094291A1 (en) * 2006-12-21 2009-09-02 Novo Nordisk A/S Dimeric prolactin receptor ligands
WO2009089537A2 (en) * 2008-01-11 2009-07-16 Northwestern University Anti-cancer compounds
US8754035B2 (en) * 2009-02-26 2014-06-17 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells

Also Published As

Publication number Publication date
JP2016029110A (ja) 2016-03-03
CN106177915A (zh) 2016-12-07
KR20140009196A (ko) 2014-01-22
JP2013544254A (ja) 2013-12-12
US8648046B2 (en) 2014-02-11
WO2012068282A1 (en) 2012-05-24
JP6306886B2 (ja) 2018-04-04
EP2640412B1 (en) 2017-08-02
IL226271A0 (en) 2013-07-31
AU2011328935B2 (en) 2016-08-11
EP2640412A1 (en) 2013-09-25
JP2018062527A (ja) 2018-04-19
AU2011328935A1 (en) 2013-05-30
US20130231286A1 (en) 2013-09-05
CN103298481A (zh) 2013-09-11
US20110065639A1 (en) 2011-03-17
CA2817846A1 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
IL272687A (en) Cancer treatment methods using PD-L1 axis binding antagonists and VEGF antagonists
IL226271A (en) The prolactin receptor antagonist and chemotherapy drug for ovarian cancer treatment
IL227308A0 (en) Use of tlr receptor agonists for cancer treatment
IL221620A (en) Antagonist antibodies against the interleukin receptor 7 and methods for their use
IL228506A (en) Opioid receptor ligands and pharmacy preparations containing them
ZA201202500B (en) Use of toll-like receptor and agonist for treating cancer
GB201002370D0 (en) Percutaneous drug delivery apparatus
IL222176B (en) Radioprotector compounds and methods
PL2716291T3 (pl) Połączenie opioidów i leków przeciwnowotworowych do leczenia nowotworów
IL279626A (en) Increasing the bioavailability of a drug in treatment with naltrexone
PL2878330T3 (pl) Aparaty do podawania leków przez skórę
ZA201309683B (en) Neutraling prolactin receptor antibody mat3 and its therapeutic use
SG11201400976WA (en) Methods and pharmaceutical compositions for treating cancer
ZA201209537B (en) Pharmaceutical composition for treating drug addiction
EP2902027A4 (en) ACTIVE COMPOSITION FOR THE TREATMENT OF TUMORS AND THE USE THEREOF
AP2015008569A0 (en) Mobile ore slurrying apparatus
GB201109965D0 (en) Materials and methods for treating estrogen receptor alpher(ER) positive cancer
GB201203681D0 (en) Androgen receptor antagonists for treatment of prostate cancer
SG10201601715YA (en) Novel Pharmaceutical Combinations And Methods For Treating Cancer
HK1190969A (en) Use of toll-like receptor agonist for treating cancer

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed